Australia's LTR Pharma rises on distribution deal for its erectile dysfunction product

Ltr Pharma

22/01/2025 01:22

** Shares of LTR Pharma  LTP.AX  rise 7.9% to A$0.755
    ** The biopharmaceutical firm rose as much as 17.9% earlier
in the day, their biggest intraday gain since early November
    ** Co enters an agreement with Australian pharmaceutical
wholesaler Symbion for nation-wide distribution for SPONTAN
    ** SPONTAN is LTR Pharma's lead product for treatment of
erectile dysfunction
    ** About 1.2 mln shares change hands, compared with 30-day
average trading volume of 669,941 shares 
    ** Stock down 13.6% YTD, as of last close 
   

 (Reporting by John Biju in Bengaluru)
 ((John.Biju@thomsonreuters.com;))